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Background: The benefits and risks of an anticoagulant in ACS may depend on whether it is supporting PCI.
methods: In a post-hoc analysis, we compared the novel, intravenous factor Xa inhibitor otamixaban (OTAM) vs. unfractionated heparin (UFH) + 
eptifibatide (EPT) on efficacy (death/MI) and safety (TIMI non-CABG major/minor bleeding) through 7 d in NSTE-ACS patients in SEPIA-ACS1 TIMI 
42, focusing on the pooled OTAM doses (0.105 & 0.140 mg/kg/h) similar to those being carried forward in phase 3 and stratifying patients by PCI 
(n=1101) or not (n=668).
results: 98% of patients underwent angiography, 63% PCI, 4% CABG, and 33% medical therapy alone. Regardless of PCI, the pooled doses of OTAM 
significantly reduced death/MI (RR 0.54, P=0.02) w/o increasing bleeding (RR 1.20, P=0.56) compared to UFH+EPT. The benefit of OTAM in reducing 
death/MI was consistent regardless of PCI (PCI: RR 0.65; No PCI: RR 0.36; P-interaction=0.32). Bleeding rates tended to be higher with OTAM vs 
UFH+EPT in patients undergoing PCI (RR 1.56, 95% 0.69-3.50) whereas they tended to be lower in those not undergoing PCI (RR 0.73, 95% CI 0.26-
2.07), with no significant heterogeneity (P-interaction=0.26). Among all patients, use of radial access (21%) was associated with lower bleeding 
rates (1.3 % vs. 3.6%, P=0.03).
conclusions: The doses of OTAM being carried forward in the ongoing phase 3 TAO trial may offer an attractive alternative to UFH+EPT in patients 
with NSTEACS regardless of whether they undergo PCI; radial access may mitigate bleeding.
 
